nodes	percent_of_prediction	percent_of_DWPC	metapath
Levomilnacipran—ABCB1—esophageal cancer	0.636	1	CbGaD
Levomilnacipran—Hypertensive crisis—Capecitabine—esophageal cancer	0.0045	0.036	CcSEcCtD
Levomilnacipran—Panic attack—Capecitabine—esophageal cancer	0.00335	0.0269	CcSEcCtD
Levomilnacipran—Night sweats—Capecitabine—esophageal cancer	0.00231	0.0185	CcSEcCtD
Levomilnacipran—Infection—Carboplatin—esophageal cancer	0.00205	0.0164	CcSEcCtD
Levomilnacipran—Supraventricular tachycardia—Capecitabine—esophageal cancer	0.0019	0.0153	CcSEcCtD
Levomilnacipran—Body temperature increased—Carboplatin—esophageal cancer	0.00163	0.013	CcSEcCtD
Levomilnacipran—Contusion—Capecitabine—esophageal cancer	0.00143	0.0115	CcSEcCtD
Levomilnacipran—Proteinuria—Capecitabine—esophageal cancer	0.00142	0.0114	CcSEcCtD
Levomilnacipran—Chest discomfort—Capecitabine—esophageal cancer	0.00141	0.0113	CcSEcCtD
Levomilnacipran—Protein urine present—Capecitabine—esophageal cancer	0.0014	0.0112	CcSEcCtD
Levomilnacipran—Gastrooesophageal reflux disease—Capecitabine—esophageal cancer	0.00138	0.0111	CcSEcCtD
Levomilnacipran—Ventricular extrasystoles—Capecitabine—esophageal cancer	0.00138	0.0111	CcSEcCtD
Levomilnacipran—Renal failure acute—Cisplatin—esophageal cancer	0.00133	0.0107	CcSEcCtD
Levomilnacipran—Blood pressure increased—Capecitabine—esophageal cancer	0.00125	0.01	CcSEcCtD
Levomilnacipran—Hyponatraemia—Cisplatin—esophageal cancer	0.00123	0.00989	CcSEcCtD
Levomilnacipran—Irritability—Cisplatin—esophageal cancer	0.00117	0.0094	CcSEcCtD
Levomilnacipran—Dry eye—Capecitabine—esophageal cancer	0.00115	0.00924	CcSEcCtD
Levomilnacipran—Breast disorder—Cisplatin—esophageal cancer	0.00111	0.0089	CcSEcCtD
Levomilnacipran—Proteinuria—Methotrexate—esophageal cancer	0.00106	0.00847	CcSEcCtD
Levomilnacipran—Protein urine present—Methotrexate—esophageal cancer	0.00104	0.00836	CcSEcCtD
Levomilnacipran—Renal failure acute—Capecitabine—esophageal cancer	0.000981	0.00786	CcSEcCtD
Levomilnacipran—Libido decreased—Capecitabine—esophageal cancer	0.000977	0.00783	CcSEcCtD
Levomilnacipran—Hot flush—Capecitabine—esophageal cancer	0.000969	0.00776	CcSEcCtD
Levomilnacipran—Menopausal symptoms—Capecitabine—esophageal cancer	0.00096	0.00769	CcSEcCtD
Levomilnacipran—Thirst—Capecitabine—esophageal cancer	0.000952	0.00763	CcSEcCtD
Levomilnacipran—Hyponatraemia—Capecitabine—esophageal cancer	0.00091	0.00729	CcSEcCtD
Levomilnacipran—Cystitis noninfective—Methotrexate—esophageal cancer	0.000908	0.00727	CcSEcCtD
Levomilnacipran—Disturbance in sexual arousal—Capecitabine—esophageal cancer	0.000899	0.0072	CcSEcCtD
Levomilnacipran—Cystitis—Methotrexate—esophageal cancer	0.000897	0.00719	CcSEcCtD
Levomilnacipran—Hepatobiliary disease—Cisplatin—esophageal cancer	0.000896	0.00718	CcSEcCtD
Levomilnacipran—Migraine—Capecitabine—esophageal cancer	0.000892	0.00715	CcSEcCtD
Levomilnacipran—Irritability—Capecitabine—esophageal cancer	0.000865	0.00693	CcSEcCtD
Levomilnacipran—Urinary retention—Capecitabine—esophageal cancer	0.000862	0.0069	CcSEcCtD
Levomilnacipran—Bladder pain—Methotrexate—esophageal cancer	0.00084	0.00673	CcSEcCtD
Levomilnacipran—Urinary tract disorder—Cisplatin—esophageal cancer	0.00084	0.00673	CcSEcCtD
Levomilnacipran—Liver function test abnormal—Capecitabine—esophageal cancer	0.000837	0.0067	CcSEcCtD
Levomilnacipran—Connective tissue disorder—Cisplatin—esophageal cancer	0.000836	0.0067	CcSEcCtD
Levomilnacipran—Urethral disorder—Cisplatin—esophageal cancer	0.000834	0.00668	CcSEcCtD
Levomilnacipran—Dry skin—Capecitabine—esophageal cancer	0.000831	0.00666	CcSEcCtD
Levomilnacipran—Breast disorder—Capecitabine—esophageal cancer	0.000819	0.00656	CcSEcCtD
Levomilnacipran—Eye disorder—Cisplatin—esophageal cancer	0.000795	0.00637	CcSEcCtD
Levomilnacipran—Cardiac disorder—Cisplatin—esophageal cancer	0.000789	0.00632	CcSEcCtD
Levomilnacipran—Flushing—Cisplatin—esophageal cancer	0.000789	0.00632	CcSEcCtD
Levomilnacipran—Abdominal distension—Capecitabine—esophageal cancer	0.000788	0.00632	CcSEcCtD
Levomilnacipran—Mediastinal disorder—Cisplatin—esophageal cancer	0.000766	0.00614	CcSEcCtD
Levomilnacipran—Angina pectoris—Capecitabine—esophageal cancer	0.000763	0.00611	CcSEcCtD
Levomilnacipran—Malnutrition—Cisplatin—esophageal cancer	0.00074	0.00593	CcSEcCtD
Levomilnacipran—Dysuria—Capecitabine—esophageal cancer	0.000732	0.00587	CcSEcCtD
Levomilnacipran—Neutropenia—Capecitabine—esophageal cancer	0.000732	0.00587	CcSEcCtD
Levomilnacipran—Renal failure acute—Methotrexate—esophageal cancer	0.000731	0.00585	CcSEcCtD
Levomilnacipran—Flatulence—Cisplatin—esophageal cancer	0.000729	0.00585	CcSEcCtD
Levomilnacipran—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.000728	0.00583	CcSEcCtD
Levomilnacipran—Weight decreased—Capecitabine—esophageal cancer	0.000708	0.00568	CcSEcCtD
Levomilnacipran—Vision blurred—Cisplatin—esophageal cancer	0.000698	0.00559	CcSEcCtD
Levomilnacipran—Tremor—Cisplatin—esophageal cancer	0.000694	0.00556	CcSEcCtD
Levomilnacipran—Stevens-Johnson syndrome—Capecitabine—esophageal cancer	0.000692	0.00555	CcSEcCtD
Levomilnacipran—Urinary tract infection—Capecitabine—esophageal cancer	0.000679	0.00544	CcSEcCtD
Levomilnacipran—Haematuria—Capecitabine—esophageal cancer	0.000666	0.00534	CcSEcCtD
Levomilnacipran—Leukopenia—Cisplatin—esophageal cancer	0.000663	0.00531	CcSEcCtD
Levomilnacipran—Hepatobiliary disease—Capecitabine—esophageal cancer	0.00066	0.00529	CcSEcCtD
Levomilnacipran—Irritability—Methotrexate—esophageal cancer	0.000644	0.00516	CcSEcCtD
Levomilnacipran—Convulsion—Cisplatin—esophageal cancer	0.000641	0.00514	CcSEcCtD
Levomilnacipran—Anxiety—Cisplatin—esophageal cancer	0.000628	0.00503	CcSEcCtD
Levomilnacipran—Hepatitis—Capecitabine—esophageal cancer	0.000627	0.00502	CcSEcCtD
Levomilnacipran—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000626	0.00502	CcSEcCtD
Levomilnacipran—Hypoaesthesia—Capecitabine—esophageal cancer	0.000624	0.005	CcSEcCtD
Levomilnacipran—Liver function test abnormal—Methotrexate—esophageal cancer	0.000623	0.00499	CcSEcCtD
Levomilnacipran—Urinary tract disorder—Capecitabine—esophageal cancer	0.000619	0.00496	CcSEcCtD
Levomilnacipran—Oedema peripheral—Capecitabine—esophageal cancer	0.000617	0.00495	CcSEcCtD
Levomilnacipran—Connective tissue disorder—Capecitabine—esophageal cancer	0.000616	0.00494	CcSEcCtD
Levomilnacipran—Urethral disorder—Capecitabine—esophageal cancer	0.000614	0.00492	CcSEcCtD
Levomilnacipran—Breast disorder—Methotrexate—esophageal cancer	0.00061	0.00488	CcSEcCtD
Levomilnacipran—Infection—Cisplatin—esophageal cancer	0.0006	0.00481	CcSEcCtD
Levomilnacipran—Erythema multiforme—Capecitabine—esophageal cancer	0.000593	0.00475	CcSEcCtD
Levomilnacipran—Nervous system disorder—Cisplatin—esophageal cancer	0.000592	0.00475	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Cisplatin—esophageal cancer	0.000592	0.00474	CcSEcCtD
Levomilnacipran—Tachycardia—Cisplatin—esophageal cancer	0.00059	0.00472	CcSEcCtD
Levomilnacipran—Skin disorder—Cisplatin—esophageal cancer	0.000587	0.0047	CcSEcCtD
Levomilnacipran—Eye disorder—Capecitabine—esophageal cancer	0.000586	0.00469	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Cisplatin—esophageal cancer	0.000584	0.00468	CcSEcCtD
Levomilnacipran—Cardiac disorder—Capecitabine—esophageal cancer	0.000582	0.00466	CcSEcCtD
Levomilnacipran—Flushing—Capecitabine—esophageal cancer	0.000582	0.00466	CcSEcCtD
Levomilnacipran—Anorexia—Cisplatin—esophageal cancer	0.000576	0.00461	CcSEcCtD
Levomilnacipran—Angiopathy—Capecitabine—esophageal cancer	0.000569	0.00456	CcSEcCtD
Levomilnacipran—Mediastinal disorder—Capecitabine—esophageal cancer	0.000565	0.00453	CcSEcCtD
Levomilnacipran—Hypotension—Cisplatin—esophageal cancer	0.000565	0.00452	CcSEcCtD
Levomilnacipran—Chills—Capecitabine—esophageal cancer	0.000562	0.00451	CcSEcCtD
Levomilnacipran—Mental disorder—Capecitabine—esophageal cancer	0.000549	0.0044	CcSEcCtD
Levomilnacipran—Malnutrition—Capecitabine—esophageal cancer	0.000546	0.00437	CcSEcCtD
Levomilnacipran—Dysuria—Methotrexate—esophageal cancer	0.000545	0.00437	CcSEcCtD
Levomilnacipran—Neutropenia—Methotrexate—esophageal cancer	0.000545	0.00437	CcSEcCtD
Levomilnacipran—Paraesthesia—Cisplatin—esophageal cancer	0.000542	0.00435	CcSEcCtD
Levomilnacipran—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.000542	0.00434	CcSEcCtD
Levomilnacipran—Dyspnoea—Cisplatin—esophageal cancer	0.000539	0.00432	CcSEcCtD
Levomilnacipran—Flatulence—Capecitabine—esophageal cancer	0.000538	0.00431	CcSEcCtD
Levomilnacipran—Erectile dysfunction—Methotrexate—esophageal cancer	0.000537	0.0043	CcSEcCtD
Levomilnacipran—Dysgeusia—Capecitabine—esophageal cancer	0.000534	0.00428	CcSEcCtD
Levomilnacipran—Decreased appetite—Cisplatin—esophageal cancer	0.000525	0.00421	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000522	0.00418	CcSEcCtD
Levomilnacipran—Stevens-Johnson syndrome—Methotrexate—esophageal cancer	0.000515	0.00413	CcSEcCtD
Levomilnacipran—Vision blurred—Capecitabine—esophageal cancer	0.000514	0.00412	CcSEcCtD
Levomilnacipran—Tremor—Capecitabine—esophageal cancer	0.000511	0.0041	CcSEcCtD
Levomilnacipran—Haematuria—Methotrexate—esophageal cancer	0.000496	0.00397	CcSEcCtD
Levomilnacipran—Hepatobiliary disease—Methotrexate—esophageal cancer	0.000492	0.00394	CcSEcCtD
Levomilnacipran—Syncope—Capecitabine—esophageal cancer	0.000489	0.00392	CcSEcCtD
Levomilnacipran—Leukopenia—Capecitabine—esophageal cancer	0.000488	0.00391	CcSEcCtD
Levomilnacipran—Palpitations—Capecitabine—esophageal cancer	0.000482	0.00386	CcSEcCtD
Levomilnacipran—Loss of consciousness—Capecitabine—esophageal cancer	0.00048	0.00384	CcSEcCtD
Levomilnacipran—Body temperature increased—Cisplatin—esophageal cancer	0.000478	0.00383	CcSEcCtD
Levomilnacipran—Hypertension—Capecitabine—esophageal cancer	0.000471	0.00378	CcSEcCtD
Levomilnacipran—Hepatitis—Methotrexate—esophageal cancer	0.000467	0.00374	CcSEcCtD
Levomilnacipran—Chest pain—Capecitabine—esophageal cancer	0.000465	0.00372	CcSEcCtD
Levomilnacipran—Anxiety—Capecitabine—esophageal cancer	0.000463	0.00371	CcSEcCtD
Levomilnacipran—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000461	0.0037	CcSEcCtD
Levomilnacipran—Urinary tract disorder—Methotrexate—esophageal cancer	0.000461	0.00369	CcSEcCtD
Levomilnacipran—Urethral disorder—Methotrexate—esophageal cancer	0.000457	0.00367	CcSEcCtD
Levomilnacipran—Dry mouth—Capecitabine—esophageal cancer	0.000454	0.00364	CcSEcCtD
Levomilnacipran—Hypersensitivity—Cisplatin—esophageal cancer	0.000445	0.00357	CcSEcCtD
Levomilnacipran—Infection—Capecitabine—esophageal cancer	0.000442	0.00355	CcSEcCtD
Levomilnacipran—Erythema multiforme—Methotrexate—esophageal cancer	0.000441	0.00354	CcSEcCtD
Levomilnacipran—Shock—Capecitabine—esophageal cancer	0.000438	0.00351	CcSEcCtD
Levomilnacipran—Nervous system disorder—Capecitabine—esophageal cancer	0.000437	0.0035	CcSEcCtD
Levomilnacipran—Eye disorder—Methotrexate—esophageal cancer	0.000436	0.00349	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Capecitabine—esophageal cancer	0.000436	0.00349	CcSEcCtD
Levomilnacipran—Tachycardia—Capecitabine—esophageal cancer	0.000435	0.00348	CcSEcCtD
Levomilnacipran—Asthenia—Cisplatin—esophageal cancer	0.000433	0.00347	CcSEcCtD
Levomilnacipran—Cardiac disorder—Methotrexate—esophageal cancer	0.000433	0.00347	CcSEcCtD
Levomilnacipran—Skin disorder—Capecitabine—esophageal cancer	0.000433	0.00347	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Capecitabine—esophageal cancer	0.000431	0.00345	CcSEcCtD
Levomilnacipran—Anorexia—Capecitabine—esophageal cancer	0.000424	0.0034	CcSEcCtD
Levomilnacipran—Angiopathy—Methotrexate—esophageal cancer	0.000423	0.00339	CcSEcCtD
Levomilnacipran—Mediastinal disorder—Methotrexate—esophageal cancer	0.000421	0.00337	CcSEcCtD
Levomilnacipran—Chills—Methotrexate—esophageal cancer	0.000419	0.00336	CcSEcCtD
Levomilnacipran—Hypotension—Capecitabine—esophageal cancer	0.000416	0.00333	CcSEcCtD
Levomilnacipran—Diarrhoea—Cisplatin—esophageal cancer	0.000413	0.00331	CcSEcCtD
Levomilnacipran—Mental disorder—Methotrexate—esophageal cancer	0.000409	0.00328	CcSEcCtD
Levomilnacipran—Malnutrition—Methotrexate—esophageal cancer	0.000406	0.00326	CcSEcCtD
Levomilnacipran—Insomnia—Capecitabine—esophageal cancer	0.000403	0.00323	CcSEcCtD
Levomilnacipran—Paraesthesia—Capecitabine—esophageal cancer	0.0004	0.0032	CcSEcCtD
Levomilnacipran—Dysgeusia—Methotrexate—esophageal cancer	0.000398	0.00319	CcSEcCtD
Levomilnacipran—Dyspnoea—Capecitabine—esophageal cancer	0.000397	0.00318	CcSEcCtD
Levomilnacipran—Dyspepsia—Capecitabine—esophageal cancer	0.000392	0.00314	CcSEcCtD
Levomilnacipran—Decreased appetite—Capecitabine—esophageal cancer	0.000387	0.0031	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000384	0.00308	CcSEcCtD
Levomilnacipran—Vomiting—Cisplatin—esophageal cancer	0.000384	0.00308	CcSEcCtD
Levomilnacipran—Fatigue—Capecitabine—esophageal cancer	0.000384	0.00308	CcSEcCtD
Levomilnacipran—Vision blurred—Methotrexate—esophageal cancer	0.000383	0.00307	CcSEcCtD
Levomilnacipran—Rash—Cisplatin—esophageal cancer	0.000381	0.00305	CcSEcCtD
Levomilnacipran—Constipation—Capecitabine—esophageal cancer	0.000381	0.00305	CcSEcCtD
Levomilnacipran—Dermatitis—Cisplatin—esophageal cancer	0.000381	0.00305	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000364	0.00292	CcSEcCtD
Levomilnacipran—Leukopenia—Methotrexate—esophageal cancer	0.000364	0.00291	CcSEcCtD
Levomilnacipran—Nausea—Cisplatin—esophageal cancer	0.000359	0.00288	CcSEcCtD
Levomilnacipran—Urticaria—Capecitabine—esophageal cancer	0.000354	0.00283	CcSEcCtD
Levomilnacipran—Abdominal pain—Capecitabine—esophageal cancer	0.000352	0.00282	CcSEcCtD
Levomilnacipran—Body temperature increased—Capecitabine—esophageal cancer	0.000352	0.00282	CcSEcCtD
Levomilnacipran—Convulsion—Methotrexate—esophageal cancer	0.000352	0.00282	CcSEcCtD
Levomilnacipran—Chest pain—Methotrexate—esophageal cancer	0.000346	0.00277	CcSEcCtD
Levomilnacipran—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000343	0.00275	CcSEcCtD
Levomilnacipran—Infection—Methotrexate—esophageal cancer	0.000329	0.00264	CcSEcCtD
Levomilnacipran—Hypersensitivity—Capecitabine—esophageal cancer	0.000328	0.00263	CcSEcCtD
Levomilnacipran—Nervous system disorder—Methotrexate—esophageal cancer	0.000325	0.00261	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Methotrexate—esophageal cancer	0.000325	0.0026	CcSEcCtD
Levomilnacipran—Skin disorder—Methotrexate—esophageal cancer	0.000322	0.00258	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Methotrexate—esophageal cancer	0.00032	0.00257	CcSEcCtD
Levomilnacipran—Asthenia—Capecitabine—esophageal cancer	0.00032	0.00256	CcSEcCtD
Levomilnacipran—Anorexia—Methotrexate—esophageal cancer	0.000316	0.00253	CcSEcCtD
Levomilnacipran—Pruritus—Capecitabine—esophageal cancer	0.000315	0.00252	CcSEcCtD
Levomilnacipran—Hypotension—Methotrexate—esophageal cancer	0.00031	0.00248	CcSEcCtD
Levomilnacipran—Diarrhoea—Capecitabine—esophageal cancer	0.000305	0.00244	CcSEcCtD
Levomilnacipran—Insomnia—Methotrexate—esophageal cancer	0.0003	0.0024	CcSEcCtD
Levomilnacipran—Paraesthesia—Methotrexate—esophageal cancer	0.000298	0.00239	CcSEcCtD
Levomilnacipran—Dyspnoea—Methotrexate—esophageal cancer	0.000296	0.00237	CcSEcCtD
Levomilnacipran—Somnolence—Methotrexate—esophageal cancer	0.000295	0.00236	CcSEcCtD
Levomilnacipran—Dizziness—Capecitabine—esophageal cancer	0.000294	0.00236	CcSEcCtD
Levomilnacipran—Dyspepsia—Methotrexate—esophageal cancer	0.000292	0.00234	CcSEcCtD
Levomilnacipran—Decreased appetite—Methotrexate—esophageal cancer	0.000288	0.00231	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000286	0.00229	CcSEcCtD
Levomilnacipran—Fatigue—Methotrexate—esophageal cancer	0.000286	0.00229	CcSEcCtD
Levomilnacipran—Vomiting—Capecitabine—esophageal cancer	0.000283	0.00227	CcSEcCtD
Levomilnacipran—Rash—Capecitabine—esophageal cancer	0.000281	0.00225	CcSEcCtD
Levomilnacipran—Dermatitis—Capecitabine—esophageal cancer	0.000281	0.00225	CcSEcCtD
Levomilnacipran—Headache—Capecitabine—esophageal cancer	0.000279	0.00224	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000271	0.00217	CcSEcCtD
Levomilnacipran—Nausea—Capecitabine—esophageal cancer	0.000265	0.00212	CcSEcCtD
Levomilnacipran—Urticaria—Methotrexate—esophageal cancer	0.000263	0.00211	CcSEcCtD
Levomilnacipran—Abdominal pain—Methotrexate—esophageal cancer	0.000262	0.0021	CcSEcCtD
Levomilnacipran—Body temperature increased—Methotrexate—esophageal cancer	0.000262	0.0021	CcSEcCtD
Levomilnacipran—Hypersensitivity—Methotrexate—esophageal cancer	0.000244	0.00196	CcSEcCtD
Levomilnacipran—Asthenia—Methotrexate—esophageal cancer	0.000238	0.00191	CcSEcCtD
Levomilnacipran—Pruritus—Methotrexate—esophageal cancer	0.000235	0.00188	CcSEcCtD
Levomilnacipran—Diarrhoea—Methotrexate—esophageal cancer	0.000227	0.00182	CcSEcCtD
Levomilnacipran—Dizziness—Methotrexate—esophageal cancer	0.000219	0.00176	CcSEcCtD
Levomilnacipran—Vomiting—Methotrexate—esophageal cancer	0.000211	0.00169	CcSEcCtD
Levomilnacipran—Rash—Methotrexate—esophageal cancer	0.000209	0.00168	CcSEcCtD
Levomilnacipran—Dermatitis—Methotrexate—esophageal cancer	0.000209	0.00167	CcSEcCtD
Levomilnacipran—Headache—Methotrexate—esophageal cancer	0.000208	0.00166	CcSEcCtD
Levomilnacipran—Nausea—Methotrexate—esophageal cancer	0.000197	0.00158	CcSEcCtD
Levomilnacipran—CYP2J2—Metabolism—GSTT1—esophageal cancer	0.000152	0.000637	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metapathway biotransformation—GSTO1—esophageal cancer	0.000152	0.000635	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—CYP2A6—esophageal cancer	0.00015	0.00063	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	0.00015	0.000627	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—BUB1B—esophageal cancer	0.00015	0.000626	CbGpPWpGaD
Levomilnacipran—CYP2C19—Biological oxidations—CYP19A1—esophageal cancer	0.000149	0.000622	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000147	0.000613	CbGpPWpGaD
Levomilnacipran—CYP2D6—Biological oxidations—CYP1B1—esophageal cancer	0.000145	0.000608	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000143	0.0006	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—ENO1—esophageal cancer	0.000143	0.000597	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—PTGS1—esophageal cancer	0.000143	0.000597	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—esophageal cancer	0.000142	0.000596	CbGpPWpGaD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	0.000141	0.000592	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—PSME1—esophageal cancer	0.000141	0.000588	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—PSME2—esophageal cancer	0.000141	0.000588	CbGpPWpGaD
Levomilnacipran—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—esophageal cancer	0.000138	0.000576	CbGpPWpGaD
Levomilnacipran—CYP2D6—Biological oxidations—CYP19A1—esophageal cancer	0.000137	0.000572	CbGpPWpGaD
Levomilnacipran—SLC6A4—Circadian rythm related genes—EP300—esophageal cancer	0.000135	0.000564	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000135	0.000564	CbGpPWpGaD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	0.000133	0.000557	CbGpPWpGaD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	0.000126	0.000528	CbGpPWpGaD
Levomilnacipran—CYP3A4—Biological oxidations—ALDH2—esophageal cancer	0.000125	0.000525	CbGpPWpGaD
Levomilnacipran—ABCB1—HIF-1-alpha transcription factor network—EP300—esophageal cancer	0.000124	0.000521	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	0.000123	0.000514	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—CYP1B1—esophageal cancer	0.000121	0.000508	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—ABL1—esophageal cancer	0.000121	0.000505	CbGpPWpGaD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—AQP3—esophageal cancer	0.00012	0.000504	CbGpPWpGaD
Levomilnacipran—CYP3A4—Biological oxidations—GSTT1—esophageal cancer	0.000119	0.000499	CbGpPWpGaD
Levomilnacipran—CYP3A4—Biological oxidations—CYP2A6—esophageal cancer	0.000118	0.000494	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—SMAD4—esophageal cancer	0.000117	0.000489	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	0.000115	0.000483	CbGpPWpGaD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	0.000115	0.000483	CbGpPWpGaD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—ATP4A—esophageal cancer	0.000115	0.000483	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—CYP19A1—esophageal cancer	0.000114	0.000477	CbGpPWpGaD
Levomilnacipran—CYP3A4—Biological oxidations—PTGS1—esophageal cancer	0.000112	0.000468	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—BAX—esophageal cancer	0.000111	0.000463	CbGpPWpGaD
Levomilnacipran—SLC6A2—Transmembrane transport of small molecules—HMOX1—esophageal cancer	0.00011	0.000459	CbGpPWpGaD
Levomilnacipran—SLC6A2—Transmembrane transport of small molecules—ABCB1—esophageal cancer	0.000105	0.000441	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—HMOX1—esophageal cancer	0.000104	0.000436	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	0.000103	0.000431	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	0.000102	0.000427	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	0.000101	0.000421	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—ABCB1—esophageal cancer	9.99e-05	0.000418	CbGpPWpGaD
Levomilnacipran—SLC6A4—Circadian rythm related genes—TP53—esophageal cancer	9.65e-05	0.000404	CbGpPWpGaD
Levomilnacipran—CYP3A4—Biological oxidations—CYP1B1—esophageal cancer	9.5e-05	0.000398	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metapathway biotransformation—CYP1B1—esophageal cancer	9.37e-05	0.000392	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	8.98e-05	0.000376	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—BLVRB—esophageal cancer	8.94e-05	0.000374	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—SLC52A3—esophageal cancer	8.94e-05	0.000374	CbGpPWpGaD
Levomilnacipran—CYP3A4—Biological oxidations—CYP19A1—esophageal cancer	8.93e-05	0.000374	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metapathway biotransformation—CYP19A1—esophageal cancer	8.81e-05	0.000369	CbGpPWpGaD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—ABCC2—esophageal cancer	8.74e-05	0.000366	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	8e-05	0.000335	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—SLC52A3—esophageal cancer	7.98e-05	0.000334	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—BLVRB—esophageal cancer	7.98e-05	0.000334	CbGpPWpGaD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—GNG7—esophageal cancer	7.93e-05	0.000332	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—esophageal cancer	7.84e-05	0.000328	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—esophageal cancer	7.81e-05	0.000327	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—BLVRB—esophageal cancer	7.79e-05	0.000326	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—SLC52A3—esophageal cancer	7.79e-05	0.000326	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—SLC10A2—esophageal cancer	7.61e-05	0.000318	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—CA1—esophageal cancer	7.61e-05	0.000318	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	7.55e-05	0.000316	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—SLC52A3—esophageal cancer	7.34e-05	0.000307	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—BLVRB—esophageal cancer	7.34e-05	0.000307	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	7.14e-05	0.000299	CbGpPWpGaD
Levomilnacipran—SLC6A2—Transmembrane transport of small molecules—CREBBP—esophageal cancer	7.04e-05	0.000295	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—CA2—esophageal cancer	6.96e-05	0.000291	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	6.8e-05	0.000285	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CA1—esophageal cancer	6.79e-05	0.000284	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—SLC10A2—esophageal cancer	6.79e-05	0.000284	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—esophageal cancer	6.73e-05	0.000282	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—CREBBP—esophageal cancer	6.68e-05	0.000279	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CA1—esophageal cancer	6.63e-05	0.000277	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—SLC10A2—esophageal cancer	6.63e-05	0.000277	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—esophageal cancer	6.54e-05	0.000274	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—ADH7—esophageal cancer	6.47e-05	0.000271	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PLCE1—esophageal cancer	6.47e-05	0.000271	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—esophageal cancer	6.39e-05	0.000268	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	6.39e-05	0.000268	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—SLC10A2—esophageal cancer	6.24e-05	0.000261	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CA1—esophageal cancer	6.24e-05	0.000261	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CA2—esophageal cancer	6.21e-05	0.00026	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	6.07e-05	0.000254	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CA2—esophageal cancer	6.06e-05	0.000254	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—NOS3—esophageal cancer	5.98e-05	0.00025	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—esophageal cancer	5.78e-05	0.000242	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—ADH7—esophageal cancer	5.77e-05	0.000242	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PLCE1—esophageal cancer	5.77e-05	0.000242	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CA2—esophageal cancer	5.71e-05	0.000239	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	5.71e-05	0.000239	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—ADH1B—esophageal cancer	5.67e-05	0.000237	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—ADH7—esophageal cancer	5.63e-05	0.000236	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PLCE1—esophageal cancer	5.63e-05	0.000236	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—esophageal cancer	5.59e-05	0.000234	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—PTGS2—esophageal cancer	5.47e-05	0.000229	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—TYMP—esophageal cancer	5.42e-05	0.000227	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—esophageal cancer	5.32e-05	0.000223	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PLCE1—esophageal cancer	5.31e-05	0.000222	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—ADH7—esophageal cancer	5.31e-05	0.000222	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—CYP26A1—esophageal cancer	5.27e-05	0.000221	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—ALOX15—esophageal cancer	5.14e-05	0.000215	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—ADH1B—esophageal cancer	5.06e-05	0.000212	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—ADH1B—esophageal cancer	4.94e-05	0.000207	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—GSTO1—esophageal cancer	4.9e-05	0.000205	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—TPI1—esophageal cancer	4.9e-05	0.000205	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—TYMP—esophageal cancer	4.84e-05	0.000202	CbGpPWpGaD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—HMOX1—esophageal cancer	4.83e-05	0.000202	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—SLC52A3—esophageal cancer	4.8e-05	0.000201	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—BLVRB—esophageal cancer	4.8e-05	0.000201	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—TYMP—esophageal cancer	4.72e-05	0.000198	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CYP26A1—esophageal cancer	4.71e-05	0.000197	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—ALDOB—esophageal cancer	4.7e-05	0.000197	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—ADH1B—esophageal cancer	4.66e-05	0.000195	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	4.63e-05	0.000194	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CYP26A1—esophageal cancer	4.59e-05	0.000192	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—ALOX15—esophageal cancer	4.59e-05	0.000192	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—EP300—esophageal cancer	4.55e-05	0.00019	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	4.53e-05	0.00019	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—GAPDH—esophageal cancer	4.52e-05	0.000189	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—CRABP1—esophageal cancer	4.48e-05	0.000188	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—ALOX15—esophageal cancer	4.48e-05	0.000187	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—TYMP—esophageal cancer	4.45e-05	0.000186	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—GSTO1—esophageal cancer	4.37e-05	0.000183	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—TPI1—esophageal cancer	4.37e-05	0.000183	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CYP26A1—esophageal cancer	4.33e-05	0.000181	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—GSTO1—esophageal cancer	4.27e-05	0.000179	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—TPI1—esophageal cancer	4.27e-05	0.000179	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—GNG7—esophageal cancer	4.26e-05	0.000178	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—ALOX15—esophageal cancer	4.22e-05	0.000177	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—ALDOB—esophageal cancer	4.19e-05	0.000176	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—ALDOB—esophageal cancer	4.09e-05	0.000171	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—SLC10A2—esophageal cancer	4.08e-05	0.000171	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CA1—esophageal cancer	4.08e-05	0.000171	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—GAPDH—esophageal cancer	4.04e-05	0.000169	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—TPI1—esophageal cancer	4.02e-05	0.000168	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—GSTO1—esophageal cancer	4.02e-05	0.000168	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CRABP1—esophageal cancer	4e-05	0.000167	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—ALDH2—esophageal cancer	4e-05	0.000167	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—GAPDH—esophageal cancer	3.94e-05	0.000165	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	3.93e-05	0.000165	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CRABP1—esophageal cancer	3.91e-05	0.000163	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—ALDOB—esophageal cancer	3.86e-05	0.000161	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—GNG7—esophageal cancer	3.81e-05	0.000159	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	3.8e-05	0.000159	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—GSTT1—esophageal cancer	3.8e-05	0.000159	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—CYP2A6—esophageal cancer	3.76e-05	0.000157	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	3.74e-05	0.000157	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CA2—esophageal cancer	3.73e-05	0.000156	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—GNG7—esophageal cancer	3.71e-05	0.000155	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—GAPDH—esophageal cancer	3.71e-05	0.000155	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CRABP1—esophageal cancer	3.68e-05	0.000154	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—ALDH2—esophageal cancer	3.57e-05	0.000149	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—ENO1—esophageal cancer	3.56e-05	0.000149	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PTGS1—esophageal cancer	3.56e-05	0.000149	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PSME2—esophageal cancer	3.51e-05	0.000147	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PSME1—esophageal cancer	3.51e-05	0.000147	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—GNG7—esophageal cancer	3.5e-05	0.000147	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—ALDH2—esophageal cancer	3.48e-05	0.000146	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PLCE1—esophageal cancer	3.47e-05	0.000145	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—ADH7—esophageal cancer	3.47e-05	0.000145	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—GSTT1—esophageal cancer	3.39e-05	0.000142	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—PIK3CA—esophageal cancer	3.36e-05	0.000141	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CYP2A6—esophageal cancer	3.35e-05	0.00014	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	3.34e-05	0.00014	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—GSTT1—esophageal cancer	3.31e-05	0.000139	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—ALDH2—esophageal cancer	3.28e-05	0.000137	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CYP2A6—esophageal cancer	3.27e-05	0.000137	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—ENO1—esophageal cancer	3.18e-05	0.000133	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PTGS1—esophageal cancer	3.18e-05	0.000133	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PSME2—esophageal cancer	3.13e-05	0.000131	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PSME1—esophageal cancer	3.13e-05	0.000131	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—GSTT1—esophageal cancer	3.12e-05	0.000131	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PTGS1—esophageal cancer	3.1e-05	0.00013	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—ENO1—esophageal cancer	3.1e-05	0.00013	CbGpPWpGaD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	3.1e-05	0.00013	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CYP2A6—esophageal cancer	3.08e-05	0.000129	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	3.06e-05	0.000128	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PSME2—esophageal cancer	3.06e-05	0.000128	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PSME1—esophageal cancer	3.06e-05	0.000128	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—ADH1B—esophageal cancer	3.04e-05	0.000127	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—CYP1B1—esophageal cancer	3.03e-05	0.000127	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—ENO1—esophageal cancer	2.92e-05	0.000122	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PTGS1—esophageal cancer	2.92e-05	0.000122	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—TYMP—esophageal cancer	2.91e-05	0.000122	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PSME2—esophageal cancer	2.88e-05	0.000121	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PSME1—esophageal cancer	2.88e-05	0.000121	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—CYP19A1—esophageal cancer	2.85e-05	0.000119	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CYP26A1—esophageal cancer	2.83e-05	0.000118	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—ALOX15—esophageal cancer	2.76e-05	0.000115	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	2.73e-05	0.000114	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CYP1B1—esophageal cancer	2.7e-05	0.000113	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CYP1B1—esophageal cancer	2.64e-05	0.00011	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—TPI1—esophageal cancer	2.63e-05	0.00011	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—GSTO1—esophageal cancer	2.63e-05	0.00011	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—HMOX1—esophageal cancer	2.6e-05	0.000109	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	2.55e-05	0.000107	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CYP19A1—esophageal cancer	2.54e-05	0.000106	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—ALDOB—esophageal cancer	2.52e-05	0.000106	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—ABCB1—esophageal cancer	2.49e-05	0.000104	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CYP1B1—esophageal cancer	2.49e-05	0.000104	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CYP19A1—esophageal cancer	2.48e-05	0.000104	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—GAPDH—esophageal cancer	2.43e-05	0.000102	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CRABP1—esophageal cancer	2.41e-05	0.000101	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CYP19A1—esophageal cancer	2.34e-05	9.78e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—HMOX1—esophageal cancer	2.32e-05	9.71e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—GNG7—esophageal cancer	2.29e-05	9.58e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	2.27e-05	9.52e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—HMOX1—esophageal cancer	2.26e-05	9.47e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—ABCB1—esophageal cancer	2.23e-05	9.32e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—ALDH2—esophageal cancer	2.14e-05	8.98e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—HMOX1—esophageal cancer	2.13e-05	8.93e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—ABCB1—esophageal cancer	2.05e-05	8.57e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—GSTT1—esophageal cancer	2.04e-05	8.54e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CYP2A6—esophageal cancer	2.02e-05	8.44e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PTGS1—esophageal cancer	1.91e-05	8e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—ENO1—esophageal cancer	1.91e-05	8e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.89e-05	7.89e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PSME2—esophageal cancer	1.88e-05	7.88e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PSME1—esophageal cancer	1.88e-05	7.88e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.68e-05	7.04e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—CREBBP—esophageal cancer	1.67e-05	6.98e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CYP1B1—esophageal cancer	1.63e-05	6.8e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CYP19A1—esophageal cancer	1.53e-05	6.4e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—NOS3—esophageal cancer	1.49e-05	6.25e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CREBBP—esophageal cancer	1.49e-05	6.23e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CREBBP—esophageal cancer	1.45e-05	6.08e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—HMOX1—esophageal cancer	1.39e-05	5.84e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CREBBP—esophageal cancer	1.37e-05	5.73e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PTGS2—esophageal cancer	1.36e-05	5.71e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—ABCB1—esophageal cancer	1.34e-05	5.6e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—NOS3—esophageal cancer	1.33e-05	5.57e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—NOS3—esophageal cancer	1.3e-05	5.44e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—NOS3—esophageal cancer	1.22e-05	5.13e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PTGS2—esophageal cancer	1.22e-05	5.1e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PTGS2—esophageal cancer	1.19e-05	4.98e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—EP300—esophageal cancer	1.13e-05	4.75e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PTGS2—esophageal cancer	1.12e-05	4.69e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—EP300—esophageal cancer	1.01e-05	4.24e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—EP300—esophageal cancer	9.89e-06	4.14e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—EP300—esophageal cancer	9.32e-06	3.9e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CREBBP—esophageal cancer	8.94e-06	3.74e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PIK3CA—esophageal cancer	8.4e-06	3.51e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—NOS3—esophageal cancer	8.01e-06	3.35e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PIK3CA—esophageal cancer	7.49e-06	3.14e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PTGS2—esophageal cancer	7.32e-06	3.07e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PIK3CA—esophageal cancer	7.31e-06	3.06e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PIK3CA—esophageal cancer	6.89e-06	2.89e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—EP300—esophageal cancer	6.09e-06	2.55e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PIK3CA—esophageal cancer	4.51e-06	1.89e-05	CbGpPWpGaD
